Relatlimab–nivolumab: A practical overview for dermatologists - 10/10/23
, Vinod E. Nambudiri, MD, MBA, EdMAbstract |
Background |
Relatlimab is a human anti-lymphocyte activation gene 3 protein antibody approved for the treatment of metastatic or unresectable melanoma in combination with nivolumab, an existing programmed cell death protein 1 inhibitor.
Objective |
In this article, we review the clinical literature on the efficacy and therapeutic use of the immune checkpoint inhibitor relatlimab in combination with nivolumab for metastatic melanoma.
Methods |
We provide an overview of the mechanism of action, clinical efficacy, and safety profile of relatlimab-nivolumab through a review of recent publications on this emerging therapeutic combination. Ongoing clinical trials studying the use of relatlimab and associated areas of active investigation are also highlighted.
Conclusion |
This review strives to inform practicing dermatologists on the use of relatlimab-nivolumab as an approved first-line dual checkpoint inhibitor for metastatic melanoma in appropriate clinical cases.
Le texte complet de cet article est disponible en PDF.Key words : BMS-986213, cutaneous oncology, immune checkpoint inhibitor, LAG-3, metastatic melanoma, nivolumab, relatlimab, targeted treatment
Abbreviations used : AEs, BRAF, FDA, IRAEs, LAG-3, LDH, pCR, PD-1, PFS, TRAEs
Plan
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
Vol 89 - N° 5
P. 1031-1037 - novembre 2023 Retour au numéro
Article précédent
- Defining and quantifying histopathologic risk factors for regional and distant metastases in a large cohort of vulvar squamous cell carcinomas
- Shayan Cheraghlou, Nicole A. Doudican, Maressa C. Criscito, Mary L. Stevenson, John A. Carucci
- Incidence and time to development of malignancies arising on the scalp of patients with erosive pustular dermatosis based on sex: A retrospective analysis
- Norhan Shamloul, Payvand Kamrani, Gelan Shamloul, Allen Kunselman, Diane Thiboutot, Elizabeth Billingsley, Charlene Lam
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?